Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer.

Article Details

Citation

Copy to clipboard

Hulin-Curtis SL, Petit D, Figg WD, Hsing AW, Reichardt JK

Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer.

Future Oncol. 2010 Dec;6(12):1897-913. doi: 10.2217/fon.10.149.

PubMed ID

21142863 [ View in PubMed

]

Abstract

Incidences of prostate cancer in most countries are increasing owing to better detection methods; however, prevention with the use of finasteride, a very effective steroid 5alpha-reductase type II inhibitor, has been met with mixed success. A wide interindividual variation in response exists and is thought to be due to heritable factors. This article summarizes the literature that attempts to elucidate the molecular mechanisms of finasteride in terms of its metabolism, excretion and interaction with endogenous steroid molecules. We describe previously reported genetic variations of steroid-metabolizing genes and their potential association with finasteride efficacy. Based on the literature, we outline directions of research that may contribute to understanding the interindividual variation in finasteride prevention and to the future development of personalized medicine.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Finasteride	Cytochrome P450 3A4	Protein	Humans	Unknown	Substrate	Details